Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news
A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan
Sunitinib has been shown to offer clinical benefits during the treatment of advanced renal cell carcinoma. However, molecular targeting drugs are expensive and can have a significant impact on medical expenses.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news
Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas
Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news
AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company âs Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news
Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news
Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news
Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.10/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news
Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news
Tall people at greater risk of cancer, study says
Colon and kidney cancer and lymphoma were among the types of cancer for which the correlation was strongest.10/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 25, 2018 Category: Urology & Nephrology Source Type: news
Eating Organic Food May Reduce Cancer Risk
A new study published in JAMA Internal Medicine suggests those who frequently eat organic foods may have a lower risk of developing cancer.10/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 25, 2018 Category: Urology & Nephrology Source Type: news
LoginSearchLATEST A look ahead to key trial readouts at ESMO
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.10/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 12, 2018 Category: Urology & Nephrology Source Type: news
8 Surprising Health Benefits of Wakame Seaweed
Wakame seaweed may have cancer-fighting properties. A study found that specific compounds extracted from the seaweed were effective at inhibiting the growth of colon and kidney cancer cells.10/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 12, 2018 Category: Urology & Nephrology Source Type: news
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.10/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 9, 2018 Category: Urology & Nephrology Source Type: news
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.10/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 8, 2018 Category: Urology & Nephrology Source Type: news
No link between progression-free survival, quality of life in cancer trials
In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and health-related quality of life, according to research published in JAMA Internal Medicine.10/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 5, 2018 Category: Urology & Nephrology Source Type: news
